🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lynda Vuong

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0002-3277-0064
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab”.

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0053
N/A
1.2DataRank · unranked
33 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.03.007
N/A
0DataRank · unranked
444 citations

Renzo G. DiNatale, Fengshen Kuo, Raghvendra M. Srivastava, Lynda Vuong, Diego Chowell +28 more

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Nature Biotechnology(2021)10.1038/s41587-021-01070-8
N/A
0DataRank · unranked
272 citations

Seong‐Keun Yoo, Cristina Valero, Alessandro Pastore, Chirag Krishna, Mark Lee +29 more

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

Nature Genetics(2022)10.1038/s41588-022-01108-w
N/A
0DataRank · unranked
79 citations

Nadeem Riaz, Robert Samstein, Mark Lee, Vladimir Makarov, Cristina Valero +29 more

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Cancer Discovery(2022)10.1158/2159-8290.cd-21-0925
N/A
0DataRank · unranked
33 citations

Lynda Vuong, Josef Leibold, Nicholas H. Chakiryan, Michael Curry, Fengshen Kuo +31 more

Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

(2023)10.1158/1541-7786.c.6545243
N/A
0DataRank · unranked
2 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

European Urology(2024)10.1016/j.eururo.2024.10.024
N/A
0DataRank · unranked
9 citations

Syed M. Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew Katims +34 more

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data

Nature Medicine(2025)10.1038/s41591-024-03398-5
N/A
0DataRank · unranked
111 citations

Conall Fitzgerald, Byuri Angela Cho, Bailey G. Fitzgerald, Catherine Y. Han, Elizabeth S. Koh +32 more

IRF8 Governs Tumor-Associated Macrophage Control of T Cell Exhaustion

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.03.12.989731
N/A
0DataRank · unranked
4 citations

Fengshen Kuo, Ming Liu, Kristelle J. Capistrano, Mytrang Do, Ruth A. Franklin +15 more

Intratumoral early activated TCF1+ CD4 Th cells drive effector CD8 T cell responses in a novel sarcomatoid RCC model through anti-CTLA4 therapy 3951

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1692
N/A
0DataRank · unranked
0 citations

Lynda Vuong, Fengshen Kuo, Doris Zheng, Alex Penson, Jing Zhang +15 more